(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 December 2005 (15.12.2005)

PCT

(10) International Publication Number
WO 2005/117891 A1

(51) International Patent Classification[7]: A61K 31/519, A61P 35/00

(21) International Application Number: PCT/US2005/019169

(22) International Filing Date: 31 May 2005 (31.05.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/521,593 30 May 2004 (30.05.2004) US

(71) Applicant *(for all designated States except US)*: **SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH** [US/US]; 1275 York Avenue, New York, NY 10021 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **O'CONNOR, Owen, A.** [US/US]; 2 Montgomery Road, Scarsdale, NY 10583 (US). **SIROTNAK, Frank** [US/US]; 2 Bayview Drive West, Hampton Bays, NY 11946 (US).

(74) Agent: **LARSON, Marina, T., PH.D**; Oppedahl & Larson LLP, P.O. Box 5068, Dillon, CO 80435-5068 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 2005/117891 A1

(54) Title: TREATMENT OF T-CELL LYMPHOMA USING 10-PROPARGYL-10-DEAZAAMINOPTERIN

(57) Abstract: T cell lymphoma is treated by administering to a patient suffering from T cell lymphoma a therapeutically effective amount of 10-propargyl-l0-deazaaminopterin. Remission is observed in human patients, even with drug resistant T cell lymphoma at weekly dosages levels as low as 30 mg/m^2. In general, the 10-propargyl-l0-deazaaminopterin is administered in an amount of from 30 to 275 mg/m^2 per dose.